Viruses as anticancer drugs

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Oncolytic viruses are being developed as anticancer drugs. They propagate selectively in tumor tissue and destroy it without causing excessive damage to normal non-cancerous tissues. When used as drugs, they must meet stringent criteria for safety and efficacy and be amenable to pharmacological study in human subjects. Specificity for neoplastic tissue is the key to safety, and this goal can be achieved through a variety of ingenious virus-engineering strategies. Antiviral immunity remains a significant barrier to the clinical efficacy of oncolytic viruses but this is being addressed by using novel immune-evasive delivery strategies and immunosuppressive drugs. Noninvasive pharmacokinetic monitoring is facilitated by engineering marker genes into the viral genome. Clinical data on the pharmacokinetics of oncolytic viruses will be the key to accelerating their development and approval as effective anticancer drugs. This review introduces concepts relevant to the use of viruses as anticancer drugs, emphasizing targeting mechanisms as well as safety and efficacy issues that are currently limiting their clinical success.

Original languageEnglish (US)
Pages (from-to)326-333
Number of pages8
JournalTrends in Pharmacological Sciences
Volume28
Issue number7
DOIs
StatePublished - Jul 2007

Fingerprint

Oncolytic Viruses
Viruses
Safety
Pharmacokinetics
Pharmaceutical Preparations
Tissue
Organ Specificity
Genes
Viral Genome
Drug Delivery Systems
Immunosuppressive Agents
Antiviral Agents
Immunity
Pharmacology
Tumors
Monitoring
Neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Viruses as anticancer drugs. / Russell, Stephen J; Peng, Kah-Whye.

In: Trends in Pharmacological Sciences, Vol. 28, No. 7, 07.2007, p. 326-333.

Research output: Contribution to journalArticle

@article{f9874292a907494088d2f269407286fa,
title = "Viruses as anticancer drugs",
abstract = "Oncolytic viruses are being developed as anticancer drugs. They propagate selectively in tumor tissue and destroy it without causing excessive damage to normal non-cancerous tissues. When used as drugs, they must meet stringent criteria for safety and efficacy and be amenable to pharmacological study in human subjects. Specificity for neoplastic tissue is the key to safety, and this goal can be achieved through a variety of ingenious virus-engineering strategies. Antiviral immunity remains a significant barrier to the clinical efficacy of oncolytic viruses but this is being addressed by using novel immune-evasive delivery strategies and immunosuppressive drugs. Noninvasive pharmacokinetic monitoring is facilitated by engineering marker genes into the viral genome. Clinical data on the pharmacokinetics of oncolytic viruses will be the key to accelerating their development and approval as effective anticancer drugs. This review introduces concepts relevant to the use of viruses as anticancer drugs, emphasizing targeting mechanisms as well as safety and efficacy issues that are currently limiting their clinical success.",
author = "Russell, {Stephen J} and Kah-Whye Peng",
year = "2007",
month = "7",
doi = "10.1016/j.tips.2007.05.005",
language = "English (US)",
volume = "28",
pages = "326--333",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Viruses as anticancer drugs

AU - Russell, Stephen J

AU - Peng, Kah-Whye

PY - 2007/7

Y1 - 2007/7

N2 - Oncolytic viruses are being developed as anticancer drugs. They propagate selectively in tumor tissue and destroy it without causing excessive damage to normal non-cancerous tissues. When used as drugs, they must meet stringent criteria for safety and efficacy and be amenable to pharmacological study in human subjects. Specificity for neoplastic tissue is the key to safety, and this goal can be achieved through a variety of ingenious virus-engineering strategies. Antiviral immunity remains a significant barrier to the clinical efficacy of oncolytic viruses but this is being addressed by using novel immune-evasive delivery strategies and immunosuppressive drugs. Noninvasive pharmacokinetic monitoring is facilitated by engineering marker genes into the viral genome. Clinical data on the pharmacokinetics of oncolytic viruses will be the key to accelerating their development and approval as effective anticancer drugs. This review introduces concepts relevant to the use of viruses as anticancer drugs, emphasizing targeting mechanisms as well as safety and efficacy issues that are currently limiting their clinical success.

AB - Oncolytic viruses are being developed as anticancer drugs. They propagate selectively in tumor tissue and destroy it without causing excessive damage to normal non-cancerous tissues. When used as drugs, they must meet stringent criteria for safety and efficacy and be amenable to pharmacological study in human subjects. Specificity for neoplastic tissue is the key to safety, and this goal can be achieved through a variety of ingenious virus-engineering strategies. Antiviral immunity remains a significant barrier to the clinical efficacy of oncolytic viruses but this is being addressed by using novel immune-evasive delivery strategies and immunosuppressive drugs. Noninvasive pharmacokinetic monitoring is facilitated by engineering marker genes into the viral genome. Clinical data on the pharmacokinetics of oncolytic viruses will be the key to accelerating their development and approval as effective anticancer drugs. This review introduces concepts relevant to the use of viruses as anticancer drugs, emphasizing targeting mechanisms as well as safety and efficacy issues that are currently limiting their clinical success.

UR - http://www.scopus.com/inward/record.url?scp=34347331167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347331167&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2007.05.005

DO - 10.1016/j.tips.2007.05.005

M3 - Article

C2 - 17573126

AN - SCOPUS:34347331167

VL - 28

SP - 326

EP - 333

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 7

ER -